CN116437904A - 芬维a胺或其类似物用于治疗肺纤维化的用途 - Google Patents

芬维a胺或其类似物用于治疗肺纤维化的用途 Download PDF

Info

Publication number
CN116437904A
CN116437904A CN202180072942.9A CN202180072942A CN116437904A CN 116437904 A CN116437904 A CN 116437904A CN 202180072942 A CN202180072942 A CN 202180072942A CN 116437904 A CN116437904 A CN 116437904A
Authority
CN
China
Prior art keywords
fenivel
aamine
analogue
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180072942.9A
Other languages
English (en)
Chinese (zh)
Inventor
拉杜·皮斯拉里乌
艾雷内吉·基亚尼卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lauren Pharmaceuticals
Original Assignee
Lauren Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lauren Pharmaceuticals filed Critical Lauren Pharmaceuticals
Publication of CN116437904A publication Critical patent/CN116437904A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180072942.9A 2020-08-25 2021-08-19 芬维a胺或其类似物用于治疗肺纤维化的用途 Pending CN116437904A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063069881P 2020-08-25 2020-08-25
US63/069,881 2020-08-25
PCT/CA2021/051148 WO2022040782A1 (en) 2020-08-25 2021-08-19 Use of fenretinide or an analogue thereof to treat pulmonary fibrosis

Publications (1)

Publication Number Publication Date
CN116437904A true CN116437904A (zh) 2023-07-14

Family

ID=80352354

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180072942.9A Pending CN116437904A (zh) 2020-08-25 2021-08-19 芬维a胺或其类似物用于治疗肺纤维化的用途

Country Status (10)

Country Link
US (1) US20230310352A1 (https=)
EP (1) EP4203931A4 (https=)
JP (1) JP2023539847A (https=)
KR (1) KR20230079054A (https=)
CN (1) CN116437904A (https=)
AU (1) AU2021329999A1 (https=)
BR (1) BR112023003481A2 (https=)
CA (1) CA3128648A1 (https=)
MX (1) MX2023002347A (https=)
WO (1) WO2022040782A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250142485A (ko) 2024-03-22 2025-09-30 경희대학교 산학협력단 폐섬유증 예방 또는 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127164A2 (en) * 2010-04-08 2011-10-13 Fate Therapeutics, Inc. Pharmaceutical compositions to treat fibrosis
TWI658830B (zh) * 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
US10406127B2 (en) * 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide

Also Published As

Publication number Publication date
BR112023003481A2 (pt) 2023-05-09
WO2022040782A1 (en) 2022-03-03
EP4203931A4 (en) 2024-11-13
JP2023539847A (ja) 2023-09-20
KR20230079054A (ko) 2023-06-05
EP4203931A1 (en) 2023-07-05
MX2023002347A (es) 2023-04-20
US20230310352A1 (en) 2023-10-05
AU2021329999A1 (en) 2023-03-23
CA3128648A1 (en) 2022-02-25

Similar Documents

Publication Publication Date Title
US20200000772A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
US10398713B2 (en) Compositions and methods for the treatment of neurodegenerative and other diseases
CA2998509A1 (en) Cenicriviroc combination therapy for the treatment of fibrosis
JP5264739B2 (ja) ポリグルタミン伸長関連疾患を治療するための塩素グアナベンズ誘導体の使用
KR20170042504A (ko) 섬유성 질환의 치료에 사용하기 위한 ppar 화합물
US20250017934A1 (en) New therapeutic combinations for the treatment of Progressive Fibrosing interstitial lung diseases
US20250025466A1 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
CN116437904A (zh) 芬维a胺或其类似物用于治疗肺纤维化的用途
US20250360181A1 (en) Use of cyclosporine analogues for treating fibrosis
JP4354180B2 (ja) 軽度認知障害治療剤
JP4045301B2 (ja) 肺胞破壊によって生じる肺疾患の治療または予防のためのクラリスロマイシンまたはその塩
KR102465736B1 (ko) 정제 및 이의 제조방법
WO2022051316A1 (en) Fixed dose combinations of chs-131 and a sglt-2 inhibitor
WO2022051318A1 (en) Fixed dose combinations of chs-131 and a thyroid receptor beta agonist
TW202410903A (zh) 治療肌肉萎縮性脊髓側索硬化症之方法及組成物
CN115137720A (zh) 瓜氨酸在制备抗焦虑药物中的应用
AU2021242812A1 (en) Use of fenretinide for the treatment of SARS-corona virus infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230714